Irritable bowel syndrome cost-effectiveness of therapy: Difference between revisions
Jump to navigation
Jump to search
(Created page with "__NOTOC__ {{Template:Irritable bowel syndrome}} {{CMG}} ==Overview== ==Cost-effectiveness of therapy== The aggregate cost of irritable bowel syndrome in the United States has...") |
m (Bot: Removing from Primary care) |
||
| (6 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{Irritable bowel syndrome}} | ||
{{CMG}} | {{CMG}} | ||
==Cost-effectiveness of therapy== | ==Cost-effectiveness of therapy== | ||
* The aggregate cost of [[Irritable bowel syndrome|IBS]] in the United States has been estimated at $1.7-$10 billion in direct medical costs, with an additional $20 billion in indirect costs, for a total of $21.7-$30 billion.<ref name="HULISZ_2004">{{cite journal | |||
The aggregate cost of | |||
| author = Hulisz D. | | author = Hulisz D. | ||
| title = The burden of illness of irritable bowel syndrome: current challenges and hope for the future. | | title = The burden of illness of irritable bowel syndrome: current challenges and hope for the future. | ||
| Line 14: | Line 13: | ||
| year =2004 | | year =2004 | ||
| id = PMID 15298528 | | id = PMID 15298528 | ||
|}} </ref> A | |}} </ref> | ||
* A 49% annual increase in medical costs is associated with a diagnosis of [[Irritable bowel syndrome|IBS]].<ref name="LEVY_2001">{{cite journal | |||
| author = Levy RL, Von Korff M, Whitehead WE, Stang P, Saunders K, Jhingran P, Barghout V, Feld AD. | | author = Levy RL, Von Korff M, Whitehead WE, Stang P, Saunders K, Jhingran P, Barghout V, Feld AD. | ||
| title = Costs of care for irritable bowel syndrome patients in a health maintenance organization | | title = Costs of care for irritable bowel syndrome patients in a health maintenance organization | ||
| Line 23: | Line 23: | ||
| year =2001 | | year =2001 | ||
| id = PMID 11721759 | | id = PMID 11721759 | ||
| }} </ref> | | }} </ref><ref name="LEONG_2003">{{cite journal |author=Leong SA, Barghout V, Birnbaum HG, ''et al''|title=The economic consequences of irritable bowel syndrome: a US employer perspective |journal=Arch. Intern. Med. |volume=163|issue=8 |pages=929–35 |year=2003 |pmid=12719202 |doi=10.1001/archinte.163.8.929}}</ref> | ||
* [[Irritable bowel syndrome|IBS]] patients have average annual direct costs of $5,049 and $406 in out-of-pocket expenses.<ref name="NYROP_2007">{{cite journal | |||
| author Nyrop KA, Palsson OS, Levy RL, Korff MV, Feld AD, Turner MJ, Whitehead WE. | | author Nyrop KA, Palsson OS, Levy RL, Korff MV, Feld AD, Turner MJ, Whitehead WE. | ||
| title = Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. | | title = Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain. | ||
| Line 32: | Line 33: | ||
| year =2007 | | year =2007 | ||
| id = PMID 17593069 | | id = PMID 17593069 | ||
| }}</ref> | | }}</ref> | ||
== | * [[Irritable bowel syndrome|IBS]] patients have a reported 34.6% loss in productivity, corresponding to 13.8 hours lost per 40 hour week.<ref name="PARE_2006">{{cite journal |author=Paré P, Gray J, Lam S, ''et al'' |title=Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study |journal=Clinical therapeutics |volume=28|issue=10 |pages=1726–35; discussion 1710–1 |year=2006 |pmid=17157129 |doi=10.1016/j.clinthera.2006.10.010}}</ref> | ||
* [[Irritable bowel syndrome|IBS]] patients have high costs for physician visits, outpatients visits, and prescription drugs. | |||
* In 2007, [[Irritable bowel syndrome|IBS]] was associated with an increase of $962 in Medicaid costs in California, and $2191 in North Carolina. | |||
* Cost of [[Irritable bowel syndrome|IBS]] is comparable to [[asthma]] patients.<ref name="MARTIN_2003">{{cite journal |author=Martin B, Ganguly R, Pannicker S, Feride F;Barghout V|title=Utilization Patterns and Net Direct Medical Costs Medicaid of Irritable Bowel Syndrome |journal=Curr Med Res Opin|volume=19 |issue=8 |pages=771-780 |year=2003|pmid=12719202 |url=http://www.medscape.com/viewarticle/465472}}</ref> | |||
==Research spending on IBS== | |||
{{ | {{Further|NIH funding of IBS Research}} | ||
* The [[National Institutes of Health]] provides a searchable database for grant awards since 1974 on its [[CRISP]] database, and provides dollar amounts for recent awards on its [http://grants.nih.gov/grants/award/trends/AggregateData.cfm Intramural Grant Award Page]. | |||
* In 2006, the NIH awarded approximately 56 grants related to [[Irritable bowel syndrome|IBS]], amounting to approximately $18,787,710. | |||
==References== | |||
{{Reflist|2}} | |||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Gastroenterology]] | |||
[[Category:Ailments of unknown etiology]] | |||
[[Category:Syndromes]] | |||
[[Category:Conditions diagnosed by stool test]] | |||
[[Category:Abdominal pain]] | |||
[[Category:Needs overview]] | |||
Latest revision as of 22:26, 29 July 2020
|
Irritable bowel syndrome Microchapters |
|
Differentiating Irritable bowel syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Irritable bowel syndrome cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Irritable bowel syndrome cost-effectiveness of therapy |
|
FDA on Irritable bowel syndrome cost-effectiveness of therapy |
|
CDC on Irritable bowel syndrome cost-effectiveness of therapy |
|
Irritable bowel syndrome cost-effectiveness of therapy in the news |
|
Blogs on Irritable bowel syndrome cost-effectiveness of therapy |
|
Risk calculators and risk factors for Irritable bowel syndrome cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Cost-effectiveness of therapy
- The aggregate cost of IBS in the United States has been estimated at $1.7-$10 billion in direct medical costs, with an additional $20 billion in indirect costs, for a total of $21.7-$30 billion.[1]
- A 49% annual increase in medical costs is associated with a diagnosis of IBS.[2][3]
- IBS patients have average annual direct costs of $5,049 and $406 in out-of-pocket expenses.[4]
- IBS patients have a reported 34.6% loss in productivity, corresponding to 13.8 hours lost per 40 hour week.[5]
- IBS patients have high costs for physician visits, outpatients visits, and prescription drugs.
- In 2007, IBS was associated with an increase of $962 in Medicaid costs in California, and $2191 in North Carolina.
- Cost of IBS is comparable to asthma patients.[6]
Research spending on IBS
- The National Institutes of Health provides a searchable database for grant awards since 1974 on its CRISP database, and provides dollar amounts for recent awards on its Intramural Grant Award Page.
- In 2006, the NIH awarded approximately 56 grants related to IBS, amounting to approximately $18,787,710.
References
- ↑ Hulisz D. (2004). "The burden of illness of irritable bowel syndrome: current challenges and hope for the future". J Manag Care Pharm. 10 (4): 299–309. PMID 15298528.
- ↑ Levy RL, Von Korff M, Whitehead WE, Stang P, Saunders K, Jhingran P, Barghout V, Feld AD. (2001). "Costs of care for irritable bowel syndrome patients in a health maintenance organization". Am J Gastroenterol. 96 (11): 3122–9. PMID 11721759.
- ↑ Leong SA, Barghout V, Birnbaum HG; et al. (2003). "The economic consequences of irritable bowel syndrome: a US employer perspective". Arch. Intern. Med. 163 (8): 929–35. doi:10.1001/archinte.163.8.929. PMID 12719202.
- ↑ "Costs of health care for irritable bowel syndrome, chronic constipation, functional diarrhoea and functional abdominal pain". Aliment Pharmacol Ther. 26 (2): 237–48. 2007. PMID 17593069. Text " author Nyrop KA, Palsson OS, Levy RL, Korff MV, Feld AD, Turner MJ, Whitehead WE. " ignored (help)
- ↑ Paré P, Gray J, Lam S; et al. (2006). "Health-related quality of life, work productivity, and health care resource utilization of subjects with irritable bowel syndrome: baseline results from LOGIC (Longitudinal Outcomes Study of Gastrointestinal Symptoms in Canada), a naturalistic study". Clinical therapeutics. 28 (10): 1726–35, discussion 1710–1. doi:10.1016/j.clinthera.2006.10.010. PMID 17157129.
- ↑ Martin B, Ganguly R, Pannicker S, Feride F;Barghout V (2003). "Utilization Patterns and Net Direct Medical Costs Medicaid of Irritable Bowel Syndrome". Curr Med Res Opin. 19 (8): 771–780. PMID 12719202.